Recombinant Human IFNW1 protein

中文名： 干扰素α-II-1(IFNW1)重组蛋白
别名： IFNW1；Interferon omega-1

货号: PA1000-4074

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	IFNW1
Uniprot No	P05000
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-195aa
氨基酸序列	MALLFPLLAA LVMTSYSPVG SLGCDLPQNH GLLSRNTLVL LHQMRRISPF LCLKDRRDFR FPQEMVKGSQ LQKAHVMSVL HEMLQQIFSL FHTERSSAAW NMTLLDQLHT GLHQQLQHLE TCLLQVVGEG ESAGAISSPA LTLRRYFQGI RVYLKEKKYS DCAWEVVRME IMKSLFLSTN MQERLRSKDR DLGSS
预测分子量	22 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于IFNW1重组蛋白的3篇参考文献示例(注：部分信息为模拟虚构，实际文献需通过学术数据库检索确认)：

---

1. **文献名称**: *"Expression and characterization of recombinant human interferon omega-1 (IFNW1) in E. coli"*

**作者**: Zhang L, et al.

**摘要**: 本研究报道了在大肠杆菌系统中高效表达IFNW1重组蛋白的优化方法，通过密码子优化和温度诱导策略提升蛋白可溶性。纯化后的IFNW1在体外实验中显示出对多种病毒的抑制活性，包括疱疹病毒和乙型肝炎病毒。

2. **文献名称**: *"Antiviral activity of IFNW1 against SARS-CoV-2 in human airway epithelial cells"*

**作者**: Smith J, et al.

**摘要**: 该研究评估了重组IFNW1蛋白对新冠病毒的抗病毒效果。实验表明，IFNW1能显著降低病毒载量并抑制细胞因子风暴，提示其作为COVID-19辅助治疗的潜在价值。

3. **文献名称**: *"Structural and functional analysis of IFNW1 receptor binding domain"*

**作者**: Kim H, et al.

**摘要**: 通过X射线晶体学解析了IFNW1与其受体的结合机制，揭示了关键氨基酸残基在信号转导中的作用，为设计靶向干扰素疗法提供了结构基础。

---

如需真实文献，建议通过PubMed、Google Scholar等平台检索关键词“Interferon Omega-1 recombinant”或“IFNW1 protein”。

背景信息

Interferon omega-1 (IFNW1), a member of the type I interferon (IFN) family, is a cytokine with antiviral, immunomodulatory, and antiproliferative properties. Initially identified in the 1980s, IFNW1 shares structural and functional similarities with interferon-alpha (IFN-α) and interferon-beta (IFN-β) but is encoded by a distinct gene located on chromosome 9 in humans. It binds to the same heterodimeric receptor complex (IFNAR1/IFNAR2) as other type I IFNs, activating JAK-STAT signaling pathways to induce interferon-stimulated genes (ISGs) that orchestrate innate and adaptive immune responses.

Recombinant IFNW1 is produced through genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems (e.g., CHO cells). The choice of expression system influences post-translational modifications; mammalian systems yield glycosylated forms closer to the native protein. The recombinant protein usually consists of 145 amino acids with a molecular weight of ~21-24 kDa, depending on glycosylation status.

Notably, IFNW1 exhibits unique species specificity, showing potent activity in feline cells, which led to its veterinary application as the active component in antiviral drugs for cats. In human medicine, it has been explored for treating viral infections (e.g., hepatitis, HIV), cancers, and autoimmune disorders, though clinical adoption remains limited compared to IFN-α/β. Recent studies highlight its potential as a vaccine adjuvant and in modulating Th1/Th2 immune balance. Research continues to optimize its therapeutic window, particularly in addressing dose-limiting toxicities common to type I IFNs, such as flu-like symptoms and hematologic abnormalities.